These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 27699722)

  • 41. Imaging outcome measures for progressive multiple sclerosis trials.
    Moccia M; de Stefano N; Barkhof F
    Mult Scler; 2017 Oct; 23(12):1614-1626. PubMed ID: 29041865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessing the differential sensitivities of wave-CAIPI ViSTa myelin water fraction and magnetization transfer saturation for efficiently quantifying tissue damage in MS.
    Elkady AM; Wu Z; Leppert IR; Arnold DL; Narayanan S; Rudko DA
    Mult Scler Relat Disord; 2021 Nov; 56():103309. PubMed ID: 34688179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
    Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K
    Eur J Neurol; 2021 Dec; 28(12):4153-4166. PubMed ID: 34487400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myelin quantification with MRI: A systematic review of accuracy and reproducibility.
    van der Weijden CWJ; García DV; Borra RJH; Thurner P; Meilof JF; van Laar PJ; Dierckx RAJO; Gutmann IW; de Vries EFJ
    Neuroimage; 2021 Feb; 226():117561. PubMed ID: 33189927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
    Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
    Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent developments in imaging of multiple sclerosis.
    Poloni G; Minagar A; Haacke EM; Zivadinov R
    Neurologist; 2011 Jul; 17(4):185-204. PubMed ID: 21712664
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spinal-cord MRI in multiple sclerosis.
    Lycklama G; Thompson A; Filippi M; Miller D; Polman C; Fazekas F; Barkhof F
    Lancet Neurol; 2003 Sep; 2(9):555-62. PubMed ID: 12941578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Whole brain and grey matter volume of Japanese patients with multiple sclerosis.
    Akaishi T; Nakashima I; Mugikura S; Aoki M; Fujihara K
    J Neuroimmunol; 2017 May; 306():68-75. PubMed ID: 28385190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord.
    Eden D; Gros C; Badji A; Dupont SM; De Leener B; Maranzano J; Zhuoquiong R; Liu Y; Granberg T; Ouellette R; Stawiarz L; Hillert J; Talbott J; Bannier E; Kerbrat A; Edan G; Labauge P; Callot V; Pelletier J; Audoin B; Rasoanandrianina H; Brisset JC; Valsasina P; Rocca MA; Filippi M; Bakshi R; Tauhid S; Prados F; Yiannakas M; Kearney H; Ciccarelli O; Smith SA; Andrada Treaba C; Mainero C; Lefeuvre J; Reich DS; Nair G; Shepherd TM; Charlson E; Tachibana Y; Hori M; Kamiya K; Chougar L; Narayanan S; Cohen-Adad J
    Brain; 2019 Mar; 142(3):633-646. PubMed ID: 30715195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MRI differential diagnosis of suspected multiple sclerosis.
    Chen JJ; Carletti F; Young V; Mckean D; Quaghebeur G
    Clin Radiol; 2016 Sep; 71(9):815-27. PubMed ID: 27349475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI.
    Kitzler HH; Su J; Zeineh M; Harper-Little C; Leung A; Kremenchutzky M; Deoni SC; Rutt BK
    Neuroimage; 2012 Feb; 59(3):2670-7. PubMed ID: 21920444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis.
    Tsagkas C; Huck-Horvath A; Cagol A; Haas T; Barakovic M; Amann M; Ruberte E; Melie-Garcia L; Weigel M; Pezold S; Schlaeger R; Kuhle J; Sprenger T; Kappos L; Bieri O; Cattin P; Granziera C; Parmar K
    Mult Scler; 2023 May; 29(6):702-718. PubMed ID: 36550626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Impact of MRI T1 Hypointense Brain Lesions on Cerebral Deep Gray Matter Volume Measures in Multiple Sclerosis.
    Buyukturkoglu K; Mormina E; De Jager PL; Riley CS; Leavitt VM
    J Neuroimaging; 2019 Jul; 29(4):458-462. PubMed ID: 30892794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.
    Sastre-Garriga J; Pareto D; Battaglini M; Rocca MA; Ciccarelli O; Enzinger C; Wuerfel J; Sormani MP; Barkhof F; Yousry TA; De Stefano N; Tintoré M; Filippi M; Gasperini C; Kappos L; Río J; Frederiksen J; Palace J; Vrenken H; Montalban X; Rovira À;
    Nat Rev Neurol; 2020 Mar; 16(3):171-182. PubMed ID: 32094485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advanced Diffusion MR Imaging for Multiple Sclerosis in the Brain and Spinal Cord.
    Hori M; Maekawa T; Kamiya K; Hagiwara A; Goto M; Takemura MY; Fujita S; Andica C; Kamagata K; Cohen-Adad J; Aoki S
    Magn Reson Med Sci; 2022 Mar; 21(1):58-70. PubMed ID: 35173096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis.
    Newbould RD; Nicholas R; Thomas CL; Quest R; Lee JS; Honeyfield L; Colasanti A; Malik O; Mattoscio M; Matthews PM; Sormani MP; Waldman AD; Muraro PA
    Neuroimage Clin; 2014; 4():641-8. PubMed ID: 24936415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hallmarks of spinal cord pathology in multiple sclerosis.
    Kreiter D; Postma AA; Hupperts R; Gerlach O
    J Neurol Sci; 2024 Jan; 456():122846. PubMed ID: 38142540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
    Cawley N; Tur C; Prados F; Plantone D; Kearney H; Abdel-Aziz K; Ourselin S; Wheeler-Kingshott CAG; Miller DH; Thompson AJ; Ciccarelli O
    Mult Scler; 2018 Jun; 24(7):932-941. PubMed ID: 28516804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of magnetic resonance techniques in understanding and managing multiple sclerosis.
    Miller DH; Grossman RI; Reingold SC; McFarland HF
    Brain; 1998 Jan; 121 ( Pt 1)():3-24. PubMed ID: 9549485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.